Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Sofosbuvir / Velpatasvir (Epclusa & authorized generic by Year
Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — U.S. sales ($M) ($M)
Gilead Sciences Sofosbuvir / Velpatasvir (Epclusa & authorized generic: $636M in FY2025, down 31.0% from a year earlier. That is the lowest of the 10 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sofosbuvir / Velpatasvir (Epclusa & authorized generic — HCV) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 636 | -31.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 922 | +7.3% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 859 | +1.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 844 | +3.6% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 815 | -5.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 864 | -11.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 971 | +4.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 934 | -61.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 2,404 | +51.1% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1,591 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Sofosbuvir / Velpatasvir (Epclusa & authorized generic ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-epclusa-us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.